On the Road to BioPharma 4.0
There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
Beating the Capacity Crunch: Rethinking the Biopharma Supply Chain to Avoid Shortages
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.
Adapting to the Challenge COVID-19 Presents to Create a New Biopharma Normal
In a recent Forbes article, Danaher’s Chief Science officer, Jose-Carlos Gutierrez-Ramos, described the impact of the COVID-19 pandemic as follows:“I believe the biopharma business model has fundamentally changed.
Drug Safety and the Public Consciousness
The public consciousness has been flooded with awareness of the previously niche concerns of quality control in drug manufacturing.
Biologics are Changing Our World. How Can We Speed Up Their Development?
The global pandemic is shining a spotlight on the power of biologics, both vaccines and antibody therapeutics, to prevent serious infections and treat disease.
The Importance of Digitization in Biopharma
Automation in a vaccine lab is not enough The ultimate goal in the biopharma space, especially for vaccine manufacturers, is producing safe and effective therapies faster, and at a lower cost. Many professionals still believe that their competitive edge relies on…
Powerful Software Can Help Biotech Companies through the COVID-19 Pandemic
In response to the outbreak, governments around the world have put strict measures in place to limit the spread of the virus – Italy was the first country to order a country-wide lock down, France closed its borders and PM…
Addressing the Challenges of Advanced Therapy R&D
In recent years, gene therapies, gene-modified cell therapies and cell therapies, collectively known as ‘Advanced Therapies’, have rapidly become an integral part of the R&D programs of many Biopharmaceutical companies. This is illustrated by some of the key trends…
Where East Meets West – The Future of CROs
Western CROs continue to up their game. They are offering unique services in a marketplace where the big CROs of the east are providing an unsurpassed scale of resourcing to support the externalization of discovery services. I believe there is…
i3 Nashville Secrets for i3 London
Want to know a secret? In September we hosted a very large group of IDBS customers from the US at i3 Nashville. Customers from every R&D industry sharing experiences, lessons learned, and business challenges. So, are you going to…
